List of Excipients in Branded Drug CORTISPORIN TC

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Endo USA Inc	CORTISPORIN TC	colistin sulfate, neomycin sulfate, thonzonium bromide and hydrocortisone acetate	63481-529	ACETIC ACID
Endo USA Inc	CORTISPORIN TC	colistin sulfate, neomycin sulfate, thonzonium bromide and hydrocortisone acetate	63481-529	POLYSORBATE 80
Endo USA Inc	CORTISPORIN TC	colistin sulfate, neomycin sulfate, thonzonium bromide and hydrocortisone acetate	63481-529	SODIUM ACETATE
Endo USA Inc	CORTISPORIN TC	colistin sulfate, neomycin sulfate, thonzonium bromide and hydrocortisone acetate	63481-529	THIMEROSAL

Cortisporin-TC Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 9, 2026

Cortisporin-TC is a legacy otic suspension combining neomycin, polymyxin B, hydrocortisone, and thonzonium bromide. Its commercial differentiation depends less on active-ingredient exclusivity than on suspension stability, antimicrobial preservation, ear-canal tolerability, container performance, and reliable delivery into infected or inflamed tissue. The product has no meaningful biosimilar exposure and appears to have limited current patent protection. The strongest opportunities are generic substitution, authorized-generic supply, preservative or formulation improvements, and differentiated otic delivery systems.

What is Cortisporin-TC and how does it work?

Cortisporin-TC is a prescription otic suspension for bacterial ear infections accompanied by inflammation. The product combines two antibacterials with a corticosteroid:

Component	Function	Approximate concentration per mL
Neomycin sulfate	Aminoglycoside antibacterial	Equivalent to 3.5 mg neomycin
Polymyxin B sulfate	Antibacterial active against susceptible gram-negative organisms	10,000 units
Hydrocortisone	Anti-inflammatory corticosteroid	10 mg
Thonzonium bromide	Surfactant intended to improve wetting and penetration	0.5 mg

The active ingredients are suspended or dispersed in an aqueous otic vehicle. The product is intended for topical ear use and is not interchangeable with ophthalmic, injectable, oral, or systemic formulations. The labeled formulation is described in FDA product information and DailyMed labeling. [1, 2]

Cortisporin-TC differs from a simpler neomycin-polymyxin B-hydrocortisone product because of thonzonium bromide. Thonzonium is intended to lower interfacial tension, improve wetting of the ear canal, and promote contact between the formulation and affected tissue.

What excipients are used in Cortisporin-TC?

Public labeling identifies an aqueous suspension vehicle containing excipients associated with wetting, viscosity control, dispersion, preservation, and physical stability. The labeled inactive ingredients include propylene glycol, polysorbate 80, cetyl alcohol, glyceryl monostearate, sodium chloride, purified water, and formulation components associated with the thonzonium-containing suspension system. Exact excipient descriptions should be reconciled against the current approved package insert and manufacturing specifications before development decisions are made. [1, 2]

What does each excipient contribute?

Excipient or excipient class	Likely formulation role	Commercial relevance
Purified water	Continuous phase	Requires microbial control and validated water quality
Propylene glycol	Cosolvent, humectant, wetting aid	May affect tolerability and preservative performance
Polysorbate 80	Surfactant and wetting agent	Supports dispersion of hydrophobic components
Cetyl alcohol	Emulsion and suspension structure	Contributes to viscosity and physical stability
Glyceryl monostearate	Emulsifier and consistency agent	Supports vehicle structure
Sodium chloride	Tonicity adjustment	Helps control local tolerability
Thonzonium bromide	Surfactant and penetration-supporting excipient	Primary formulation differentiator
Preservative system, if present in the approved version	Microbial protection	Important for multidose packaging and regulatory comparability

The formulation challenge is not simply dissolving the active ingredients. Neomycin and polymyxin B are water-compatible salts, while hydrocortisone has low aqueous solubility. A stable product therefore requires controlled dispersion of hydrocortisone, adequate wetting, uniform dose delivery, and resistance to settling or caking.

Why is thonzonium bromide commercially important?

Thonzonium bromide is the key excipient-based differentiator in Cortisporin-TC. It is used as a cationic surfactant and wetting agent. Its strategic value is tied to three performance attributes:

1. Improved wetting of the ear canal and infected surface.
2. More uniform contact between the vehicle and tissue.
3. A formulation profile that is distinct from products containing only neomycin, polymyxin B, and hydrocortisone.

Thonzonium also creates development risk. A generic sponsor must demonstrate that the finished suspension has appropriate physical characteristics, dose uniformity, microbial quality, and performance after shaking and administration. A formulation that substitutes a different surfactant may be therapeutically acceptable but could create additional FDA review issues if the product no longer matches the reference formulation closely.

The commercial value of thonzonium is therefore practical rather than exclusivity-based. It may support product recognition and formulation similarity, but it does not by itself create a durable patent barrier.

What patent protection covers Cortisporin-TC?

The original composition, active-ingredient combination, and basic otic use are legacy technologies. The principal patent term for any early Cortisporin-TC patents would have expired decades ago under the U.S. patent term framework. Publicly available product and FDA records do not indicate a currently enforceable, commercially significant patent estate protecting the core Cortisporin-TC formulation.

Protection category	Current strategic assessment
Core drug combination	Legacy protection; no meaningful current composition patent barrier identified
Thonzonium-containing vehicle	Older formulation concept; no current blocking patent identified
Method of treating otitis externa	Likely expired or narrow legacy claims
Manufacturing process	Potential trade-secret protection, but no known blocking patent position
Container or dropper design	Could be protected separately, depending on supplier and product configuration
New preservative-free or delivery formulation	Potential new patent opportunity
FDA regulatory exclusivity	Legacy exclusivity would have expired
Biosimilar exclusivity	Not applicable; Cortisporin-TC is a small-molecule otic product

A freedom-to-operate conclusion requires a current patent search across U.S. and foreign family members, including continuation and terminal-disclaimer records. The available public record supports a low patent-barrier assessment for the legacy product, not a conclusion that every related formulation or device patent has expired.

When does Cortisporin-TC lose exclusivity?

Cortisporin-TC has no commercially relevant remaining period of new-drug exclusivity based on its legacy status. Any five-year new chemical entity exclusivity, three-year clinical-investigation exclusivity, orphan exclusivity, or pediatric exclusivity associated with the original product would have expired long ago.

The principal remaining barriers are regulatory and commercial:

• Demonstrating pharmaceutical equivalence to the reference product.
• Matching suspension and delivery performance.
• Establishing microbiological quality.
• Securing a reliable source of neomycin, polymyxin B, hydrocortisone, and thonzonium bromide.
• Managing ototoxicity warnings associated with aminoglycoside-containing otic products.
• Obtaining consistent reimbursement and pharmacy distribution.

FDA Orange Book status must be checked against the current edition and any discontinued-product annotations. Older otic products may appear in historical FDA records even when commercial availability is limited or the product is supplied through a successor labeler. [3]

Is Cortisporin-TC listed in the Orange Book?

The Orange Book generally lists approved drug products with patent and exclusivity information, but legacy topical otic products may have complex listing histories. The relevant diligence questions are:

Orange Book question	Business implication
Is the reference listed as currently marketed?	Determines whether an ANDA can rely on an active reference product
Is the product listed as discontinued?	May require a suitability or reference-product analysis
Are patents listed?	Determines Paragraph IV exposure
Is there current exclusivity?	Determines ANDA approval timing
Is the product an NDA reference or an older regulatory listing?	Affects application strategy and data requirements

No current, high-value Orange Book patent position is apparent for the core Cortisporin-TC formulation from the public legacy record. A sponsor should not assume that an unlisted patent is irrelevant. Device, packaging, manufacturing, or later reformulation patents may sit outside the principal product listing.

What Paragraph IV challenges could affect Cortisporin-TC?

A Paragraph IV challenge is likely to have limited importance if no unexpired Orange Book patents are listed against the reference product. The more likely pathway is a standard ANDA relying on the reference product’s safety and effectiveness findings, subject to FDA requirements for pharmaceutical equivalence and bioequivalence or other applicable product-performance evidence.

Potential Paragraph IV issues could arise if a later patent covers:

• A specific thonzonium concentration.
• A defined particle-size distribution for hydrocortisone.
• A preservative-free multidose suspension.
• A particular dropper or dispensing system.
• A manufacturing process that improves dose uniformity.
• A combination of excipients that improves ear-canal retention or wetting.

These claims would need to be distinguished from the broad legacy concept of combining neomycin, polymyxin B, hydrocortisone, and thonzonium.

What formulation patents could protect a next-generation product?

A new Cortisporin-TC-related product would need a defensible technical improvement. Broad claims covering the known active ingredients and excipients would face substantial prior-art risk. More credible patent strategies include:

Preservative-free suspension

A preservative-free product could target patients with sensitivity to antimicrobial preservatives and reduce excipient-related irritation. Patentable subject matter may include:

• A sterile single-use container.
• A defined particle-size range.
• A suspension system that remains redispersible without preservatives.
• A filling and aseptic-processing method.
• A container closure that limits contamination during use.

Improved suspension stability

The commercial objective would be consistent delivery of hydrocortisone and the antibacterial components throughout the labeled use period. Potential claims could cover:

• Sedimentation rate.
• Redispersibility after storage.
• Viscosity range.
• Particle-size distribution.
• Freeze-thaw stability.
• Assay uniformity after repeated shaking.

Enhanced ear-canal retention

A mucoadhesive or in-situ gelling formulation could reduce drainage and increase contact time. Candidate technologies include polymeric gels, thermoresponsive systems, and low-irritancy mucoadhesive excipients. These systems would need to avoid obstructing the canal or complicating administration.

Unit-dose packaging

Unit-dose packaging could address contamination, preservative exposure, and adherence. The commercial tradeoff is higher packaging cost and lower convenience for prolonged treatment.

Alternative delivery devices

A metered-dose dropper or dose-marked applicator could improve administration accuracy. Device claims may provide stronger protection than a conventional bottle, although device-specific patents would require separate freedom-to-operate analysis.

What manufacturing and intellectual-property barriers exist?

The active ingredients are established, but polymyxin B and thonzonium bromide can create sourcing and quality-control issues. Manufacturing barriers include:

• Maintaining polymyxin B potency and impurity control.
• Controlling hydrocortisone particle size.
• Achieving uniform dispersion in a viscous vehicle.
• Preventing caking during storage.
• Validating microbial limits and preservative effectiveness.
• Ensuring compatibility between the formulation and dropper closure.
• Controlling extractables and leachables.
• Demonstrating dose uniformity after storage and repeated shaking.

Polymyxin B is a mixture of related components rather than a single simple molecular entity. Supplier changes can affect impurity profiles, assay, and product performance. This creates an opportunity for process know-how and supplier qualification to function as practical barriers even where patent protection is weak.

Which companies could challenge or compete with Cortisporin-TC?

Competition is likely to come from three groups:

1. Generic manufacturers of neomycin-polymyxin B-hydrocortisone otic products.
2. Manufacturers of ciprofloxacin or ofloxacin otic products.
3. Branded or generic products using alternative corticosteroid-antibiotic combinations.

Cortisporin-TC competes on combination therapy and familiar prescribing behavior. Fluoroquinolone otic products compete on dosing convenience, broader bacterial coverage in some settings, and avoidance of aminoglycoside exposure. Combination products containing dexamethasone rather than hydrocortisone may compete through a different anti-inflammatory profile.

The product is more vulnerable in uncomplicated bacterial otitis externa, where lower-cost generic antibiotic-steroid products are available. Its relative position may improve where prescribers value the established combination and the thonzonium-containing vehicle.

What generic launch scenarios exist?

Launch scenario	Probability profile	Commercial requirements
Standard generic suspension	Most direct pathway	Reference-product matching, stable supply, pharmacy contracting
Authorized generic	Fastest branding substitution if available	NDA-holder or distributor agreement
Preservative-free version	Differentiated niche	New formulation development and packaging
Unit-dose product	Hospital and specialty opportunity	Higher packaging and manufacturing cost
Metered-dose delivery system	Premium differentiation	Device development and human-factors work
Thonzonium-free alternative	Formulation simplification	May lose direct product identity and require careful equivalence strategy

A conventional generic is likely to face price competition. A differentiated formulation can protect margin but increases development cost, regulatory complexity, and supply-chain requirements.

What is the revenue opportunity for Cortisporin-TC?

The product’s revenue opportunity is unlikely to come from exclusivity-driven pricing. It is more likely to arise from operational improvements:

• Reliable availability during generic shortages.
• Hospital and clinic contracts.
• Private-label supply.
• Authorized-generic distribution.
• Preservative-free positioning.
• Otic products bundled with urgent-care and ENT portfolios.
• International registration where competition is less concentrated.
• Contract manufacturing for regional pharmaceutical companies.

Revenue exposure is also constrained by the availability of lower-cost substitutes and by the small size of the otic anti-infective market relative to systemic antibiotics or ophthalmic products. A sponsor should model the product as a focused specialty or portfolio asset rather than a high-growth exclusivity asset.

How does Cortisporin-TC compare with competing otic products?

Attribute	Cortisporin-TC	Generic neomycin-polymyxin B-hydrocortisone	Fluoroquinolone otic
Antibacterial classes	Two	Two	One
Corticosteroid	Hydrocortisone	Hydrocortisone or related steroid	Often combined with dexamethasone in branded products
Thonzonium	Yes	Usually no	Usually no
Formulation identity	Suspension with surfactant vehicle	Conventional solution or suspension	Often solution
Generic price pressure	High	Very high	High to moderate
Aminoglycoside-related ototoxicity concern	Relevant	Relevant	Generally lower concern
Differentiation opportunity	Excipient and delivery system	Limited	Device, dosing, and tolerability
Biosimilar risk	None	None	None

What is the litigation and settlement outlook?

No major current patent litigation or settlement framework is apparent for the legacy Cortisporin-TC formulation. The litigation risk for a new entrant is more likely to involve:

• Patent claims on a later formulation.
• Trade-secret allegations involving suspension processing.
• Supplier confidentiality and manufacturing specifications.
• Trademark or trade-dress issues.
• ANDA litigation if a later patent is listed.
• Product-liability claims involving allergy, ototoxicity, or use with tympanic-membrane perforation.

A settlement agreement would become relevant only if a sponsor challenges a subsequently listed patent or if the product is linked to a later reformulation with active exclusivity.

Key Takeaways

• Cortisporin-TC is a legacy neomycin-polymyxin B-hydrocortisone otic suspension containing thonzonium bromide.
• Thonzonium is the principal excipient-based differentiator and supports wetting and tissue contact.
• The core product appears to have little current patent or regulatory exclusivity.
• Biosimilar competition is not relevant because the product is a small-molecule otic drug.
• A conventional generic faces substantial price competition.
• The best commercial opportunities are authorized-generic supply, preservative-free packaging, unit-dose delivery, improved suspension stability, and metered-dose administration.
• Manufacturing know-how, supplier qualification, particle-size control, and container compatibility may create more practical protection than legacy patents.
• Current Orange Book status, market availability, and any later patent listings require product-specific verification before an ANDA or licensing decision.

FAQs

Can thonzonium bromide be replaced in a Cortisporin-TC generic?

It may be technically possible, but replacing thonzonium can affect wetting, suspension performance, product identity, and the regulatory equivalence strategy. A direct generic approach would generally favor matching the reference formulation as closely as permitted.

Is Cortisporin-TC suitable for preservative-free reformulation?

Potentially. A preservative-free product would require sterile processing, suitable packaging, contamination-control validation, and evidence that the formulation remains physically and microbiologically stable throughout use.

Does hydrocortisone particle size affect Cortisporin-TC performance?

Yes. Particle size can affect suspension uniformity, sedimentation, redispersibility, dose consistency, and local drug release. It is a plausible target for formulation control and, in a new product, potentially for patent claims.

Could a unit-dose Cortisporin-TC product command a premium?

It could in hospital, urgent-care, and specialty settings where contamination control and single-patient use have value. The premium would need to offset higher filling, packaging, and distribution costs.

Is a Cortisporin-TC formulation patent likely to block a generic launch?

A legacy formulation patent is unlikely to create a major barrier if it has expired or is not listed. A later patent covering a specific excipient system, particle-size range, preservative-free package, or delivery device could create a more material risk.

References

1. U.S. Food and Drug Administration. (n.d.). Cortisporin-TC otic suspension prescribing information. FDA drug labeling database.

2. National Library of Medicine. (n.d.). Cortisporin-TC otic suspension. DailyMed.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.